Amgen Inc. / Micromet Inc.

Acute Lymphoblastic Leukemia (ALL)

6K US cases/yr

Disease Overview

Acute lymphoblastic leukemia is an aggressive blood cancer in which immature lymphoid precursors proliferate uncontrollably in the bone marrow. It is the most common pediatric cancer but carries especially poor prognosis in adults and in relapsed/refractory disease, where historical 5-year survival was under 10% before T-cell engaging therapies. CD19 expression on nearly all B-cell ALL blasts makes it a rational immunotherapy target.

Competitive Landscape

At the time of the 2012 Amgen-Micromet deal, relapsed/refractory ALL treatment relied on intensive chemotherapy regimens (hyper-CVAD, FLAG-IDA) and allogeneic stem cell transplant, with poor durable response rates. Blinatumomab (Blincyto, Amgen) was first-in-class CD19xCD3 BiTE in Phase 2 with encouraging single-agent activity, ultimately receiving FDA accelerated approval in December 2014 for Ph- R/R B-ALL. The competitive set has since expanded to include inotuzumab ozogamicin (Besponsa, Pfizer, CD22 ADC) approved 2017 and the CD19 CAR-T tisagenlecleucel (Kymriah, Novartis) approved 2017 for pediatric/young adult R/R ALL. Blinatumomab maintains the convenience advantage of an off-the-shelf bispecific versus autologous CAR-T manufacturing logistics and has expanded into MRD-positive disease and frontline consolidation. The Micromet acquisition gave Amgen the foundational BiTE platform that has since spawned tarlatamab (Imdelltra, DLL3xCD3 for SCLC, approved 2024) and an extensive bispecific pipeline, validating the deal's strategic rationale beyond the initial ALL indication and entrenching Amgen as a leader in T-cell engaging immunotherapy.